The most recent 2022 World Health Organization (WHO) classification of kidney cancers included for the first time a category of molecularly defined subtypes of RCCs, which includes TFE3-rearranged RCC and TFEB-altered RCC (translocation RCC), fumarate hydratase (FH)-deficient RCC, succinate dehydrogenase (SDH)-deficient RCC, ELOC-mutated RCC, and anaplastic lymphoma kinase (ALK)-rearranged RCC [2]. This evidence concerns the gene TFE3 and renal cell adenocarcinoma.